Tumor Microenvironment (eBook)

The Main Driver of Metabolic Adaptation
Artikelnummer: 978-3-030-34025-4
Einband: PDF
Verfügbarkeit: Download, sofort verfügbar (Link per E-Mail)
CHF 189.00
decrease increase
This book will allow readers to discover the crucial role of tumor microenvironment (TME) in the selection of cancer cells that are more prone to carry on cancer initiation and progression. The metabolic remodeling, as the basis of life overall, allows the adaptive establishment of a tumor in a certain TME, which in turn presents a variety of selective pressures. Coupled with the late diagnosis, the poor therapy response are the main hurdles limiting oncological disease control and eventual cure. Thus the metabolic plasticity of cancer cells often underlies chemoresistance.

This edited work presents an exhaustive description and comprehensive view of cancer metabolism as a weapon used by cancer cells to adapt to TME. TME and the organ microenvironment is analyzed as a whole, considering cancer cells, stromal cells and microbiota. This complex circuit is observed as the support for disease development and therapy evasion but also as a valuable kernel, presenting new playersto be targeted in a more precise cancer therapy.

The various threads of cancer biology related to TME and metabolic adaptation will be addressed including: 1) key players in the metabolic network; 2) the way adaptive metabolic features are sustained by TME; 3) TME and metabolic signaling, accounting for cancer cells survival; 4) metabolic fitness driven limitations in therapy response, and 5) the way TME and cancer metabolism can be helpful in the design of new drugs.  In addition, the usefulness, technical strengths and weaknesses of analytical techniques useful in cancer metabolomics will be presented in an integrative way. Moreover, the use of innovative and traditional in vitro and in vivo cancer models, as powerful tools to address the influence of TME in cancer progression and metabolic reprogramming will be also presented.

This work was written by experts and dedicated to researchers with interests in cancer biology, TME, cancer metabolism and therapy. It will interest the Advances in Experimental Medicine and Biology readership, including basic researchers, analytic researchers, bio-engineers and clinicians.


This book will allow readers to discover the crucial role of tumor microenvironment (TME) in the selection of cancer cells that are more prone to carry on cancer initiation and progression. The metabolic remodeling, as the basis of life overall, allows the adaptive establishment of a tumor in a certain TME, which in turn presents a variety of selective pressures. Coupled with the late diagnosis, the poor therapy response are the main hurdles limiting oncological disease control and eventual cure. Thus the metabolic plasticity of cancer cells often underlies chemoresistance.

This edited work presents an exhaustive description and comprehensive view of cancer metabolism as a weapon used by cancer cells to adapt to TME. TME and the organ microenvironment is analyzed as a whole, considering cancer cells, stromal cells and microbiota. This complex circuit is observed as the support for disease development and therapy evasion but also as a valuable kernel, presenting new playersto be targeted in a more precise cancer therapy.

The various threads of cancer biology related to TME and metabolic adaptation will be addressed including: 1) key players in the metabolic network; 2) the way adaptive metabolic features are sustained by TME; 3) TME and metabolic signaling, accounting for cancer cells survival; 4) metabolic fitness driven limitations in therapy response, and 5) the way TME and cancer metabolism can be helpful in the design of new drugs.  In addition, the usefulness, technical strengths and weaknesses of analytical techniques useful in cancer metabolomics will be presented in an integrative way. Moreover, the use of innovative and traditional in vitro and in vivo cancer models, as powerful tools to address the influence of TME in cancer progression and metabolic reprogramming will be also presented.

This work was written by experts and dedicated to researchers with interests in cancer biology, TME, cancer metabolism and therapy. It will interest the Advances in Experimental Medicine and Biology readership, including basic researchers, analytic researchers, bio-engineers and clinicians.


Schreiben Sie Ihre eigene Bewertung
  • Nur registrierte Benutzer können Produkte bewerten
*
*
Schlecht
Sehr gut
*
*
*
*
VerlagSpringer Nature Switzerland
EinbandPDF
Erscheinungsjahr2020
Seitenangabe443 S.
AusgabekennzeichenEnglisch
AbbildungenVII, 443 p. 1 illus.
Masse15'505 KB
PlattformPDF
ReiheAdvances in Experimental Medicine and Biology; Biomedical and Life Sciences; Biomedical and Life Sciences
AutorSerpa, Jacinta (Hrsg.)

Alle Bände der Reihe "Advances in Experimental Medicine and Biology; Biomedical and Life Sciences; Biomedical and Life Sciences (R0)"

Über den Autor Jacinta (Hrsg.) Serpa

Jacinta Serpa holds a degree in Biology from the University of the Azores (December 1997) and earned her PhD in Human Biology, with a specialization in glycobiology and gastric cancer, from the Faculty of Medicine, University of Porto (December 2005). With over 20 years of experience in cancer biology, she has been a faculty member at NOVA Medical School since 2008 and a researcher at the Portuguese Oncology Institute (IPOLFG) since 2006. Her research is primarily focused on cancer metabolism, particularly the metabolic reprogramming that enables cancer cell survival in specific microenvironments, and the metabolic alterations that influence therapeutic response. Since 2015, she has led the Cancer Metabolism and Microenvironment Laboratory at NOVA Medical School (NMS|FCM) and IPOLFG. Current research in her lab centers on identifying metabolic biomarkers for chemoresistance and disease prognosis, as well as discovering therapeutic targets derived from metabolic vulnerabilities. Metabolomics plays a key role in this strategy, offering insights into tumor-specific metabolic pathways. Moreover, metabolism-based therapies could be an efficient way of improving personalized medicine in cancer. Cindy Mendes is a Junior Researcher in Biomedical Sciences at NOVA University Lisbon, Portugal, where she conducts her research within the Cancer Metabolism and Microenvironment Group at the Instituto Português de Oncologia de Lisboa (IPOLFG). Her work has been focused on understanding metabolic rewiring in cancer, particularly how alterations in lactate and redox metabolism drive tumor progression and therapy resistance in cancers, including non-small cell lung, breast, and ovarian carcinomas. Her research specifically investigates how cancer cells manipulate lactate shuttle systems and redox homeostasis to maintain cellular energy production, mitigate oxidative stress, and support survival under metabolic pressure. She explores how the interplay between lactate metabolism and redox balance creates unique therapeutic vulnerabilities that can be targeted using innovative nanomedicine approaches. Her work includes applying specialized nanoparticle platforms designed to selectively deliver therapeutic agents that disrupt these critical metabolic networks. By combining fundamental research into cancer metabolism with advanced therapeutic design, her work helps bridge the gap between laboratory discovery and clinical translation. This contributes meaningfully to the growing field of metabolism-based oncology, offering new potential strategies for treating aggressive, treatment-resistant cancers. Her approach highlights the therapeutic potential of targeting cancer's metabolic adaptations, particularly through lactate and redox pathways, to develop more effective treatments for patients with limited therapeutic options. Her contributions to this field have been recognized through publications and presentations at international scientific conferences.

Weitere Titel von Jacinta (Hrsg.) Serpa

Produktbewertungen
Nur registrierte Benutzer können Produkte bewerten